Celcuity Raises $400M in Convertible Notes to Repay Debt, Fund Growth
Event summary
- Celcuity Inc. plans to raise $400M via convertible senior notes due 2032, with an option for $60M more.
- Proceeds will first repay outstanding obligations under its loan agreement with Oxford Finance.
- Remaining funds will support working capital, clinical trials, and potential acquisitions.
- Notes are unsecured, senior obligations with semi-annual interest payments.
- Closing is subject to market conditions, with no guaranteed timeline or final terms.
The big picture
Celcuity's $400M convertible notes offering underscores its push to strengthen its financial position amid clinical-stage development. The move reflects a broader trend among biotech firms to secure non-dilutive funding while maintaining flexibility for strategic growth. The scale of the offering highlights the company's ambition to not only repay existing debt but also invest heavily in its pipeline, particularly its lead candidate gedatolisib.
What we're watching
- Debt Repayment Impact
- How quickly Celcuity can repay its existing debt and the effect on its balance sheet flexibility.
- Clinical Trial Progress
- Whether the funding will accelerate the completion of key trials, particularly VIKTORIA-1 and VIKTORIA-2.
- Acquisition Strategy
- The pace at which Celcuity pursues potential acquisitions to expand its pipeline or capabilities.
Related topics